Ask Anything

Jörg Hausleiter

2mo

“

Among these high-risk patients, transcatheter tricuspid valve repair on top of medical therapy resulted not only in quality-of-life improvements but also in meaningful and sustained reductions in hard clinical outcomes, which has not been demonstrated before with the intervention.

Dr. Viktor Kočka

Interventional Cardiologist · Charles University and University Hospital Kralovske Vinohrady

2mo

“

Using the blueprint already employed for heart attacks, we were able to demonstrate that specialised interventional treatment can be delivered in tertiary care centres across our national network. This may pave the way for an improved, standardised approach to the treatment of pulmonary embolism, reducing the acute risks that patients face.

Dr. Sophia Zoungas

Lead Researcher · Monash University School of Public Health and Preventive Medicine

2mo

“

A notable finding is that the lower incidence of major, nonfatal cardiovascular events with atorvastatin than with placebo did not result in a corresponding improvement in disability-frees survival. Explanations for this result might include the fact that 80% of the deaths in the trial were from non-cardiovascular causes.

Boyoung Joung

2mo

“

The key impact on clinical practice is that the level of evidence about this population was actually very low, and this is the first [randomized controlled trial] to support that DOAC therapy can give benefit to this patient population.

Dr. Henning Bundgaard

Cardiologist · Copenhagen University Hospital

2mo

“

It seems that from POET I and POET II we have challenged dogmas showing that less intensive antibiotic therapy after stabilization is superior and safe. And we think that defining the stabilization point is a kind of personalizing endocarditis treatment.

Nick Mills

BHF Professor of Cardiology, University of Edinburgh · University of Edinburgh

7w

“

Our findings provide strong evidence that patients who have had a heart attack excluded do not benefit from early outpatient CTCA scans. Once we are confident that they haven't had a heart attack, we can reassure these patients that their future risk is low and send them home.

Dr. Matthew J. Reed

Professor of Emergency Medicine · The Usher Institute, University of Edinburgh

2mo

“

Although immediate ECG monitoring did not reduce recurrent fainting, it enabled earlier identification of serious cardiac rhythm disorders, allowing patients to receive treatment much sooner, reducing uncertainty and anxiety, and potentially preventing avoidable deaths.

Dr. Ahmad Masri

Cardiologist · Oregon Health & Science University

2mo

“

Results from the ACACIA-HCM trial provide really positive news for patients with symptomatic non-obstructive HCM. For the first time, we have shown clinically meaningful improvements in symptoms and exercise capacity with a treatment that targets the cause of the disease.

Giuseppe Biondi-Zoccai

Expert commentary · @gbiondizoccai

2w

“

In the 986-patient TAVI PCI RCT, a strategy of TAVI before PCI yielded similar outcome to a strategy of PCI before TAVI at 1 year in patients with both aortic stenosis and CAD (25% MVD) #CAD #PCI #TAVI #TAVR @NEJM @escardio

t.cot.co

Dr. Hang Zhang

Cardiologist · Nanjing First Hospital

2mo

“

Despite major advances in pharmacologic and device-based therapies, pulmonary hypertension remains one of the strongest predictors of hospitalization, right ventricular failure, and death in patients with left heart disease and heart failure. … Additional long-term follow-up will be important to determine whether the observed mid-term improvements translate into sustained reductions in mortality and hospitalization for HF.